Medindia
Medindia LOGIN REGISTER
Advertisement

DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs

Friday, May 6, 2011 General News
Advertisement

DURECT CORPORATION

STATEMENTS OF OPERATIONS DATA

(in thousands, except per share amounts)

(unaudited)

Three months ended

March 31,

2011

2010

Collaborative research and development and other revenue

$              5,512

$              3,816

Product revenue, net

3,092

3,850

Total revenues

8,604

7,666

Operating expenses:

Cost of revenues (1)

1,401

1,378

Research and development (1)

9,880

9,421

Selling, general and administrative (1)

3,716

3,502

Total operating expenses

14,997

14,301

Loss from operations

(6,393)

(6,635)

Other income (expense):

Interest and other income

40

11

Interest and other expense

(4)

(2)

Net other income

36

9

Net loss

$            (6,357)

$            (6,626)

Net loss per share, basic and diluted

$              (0.07)

$              (0.08)

Shares used in computing basic and diluted net loss per share

87,270

86,756

(1) Includes stock-based compensation related to the following:

Cost of revenues

$                   85

$                   84

Research and development

1,127

1,277

Selling, general and administrative

571

669

Total stock-based compensation

$              1,783

$              2,030

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close